Skip to main content
Clinical Trials/ACTRN12605000208606
ACTRN12605000208606
Completed
Phase 4

A two year double blind, randomised, controlled trial to evaluate the efficacy of zoledronic acid in the prevention of bone loss in patients infected with human immunodeficiency virus taking highly active antiretroviral therapy (HAART)

Associate Professor A Grey0 sites70 target enrollmentAugust 25, 2005

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
HIV-related osteopenia
Sponsor
Associate Professor A Grey
Enrollment
70
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 25, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Associate Professor A Grey

Eligibility Criteria

Inclusion Criteria

  • HIV positive and have taken HAART for at least 3 months and have a bone mineral density T score of less than \-0\.5SD at any site.

Exclusion Criteria

  • Renal impairment (serum creatinine \>0\.15 mmol/L), untreated hypothyroidism or hyperthyroidism, chronic liver disease, concurrent major systemic illness, including malignancy, active major gastrointestinal disease, metabolic bone diseases, primary hyperparathyroidism, more than 2 hospital admissions within 6 months of study entry, use of oral glucocorticoid drugs equivalent to an average dose of prednisone 2\.5 mg/day in the preceding six months.

Outcomes

Primary Outcomes

Not specified

Similar Trials